Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments

• COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS
• COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS TO EVOTEC BASED ON THE OVERALL SUCCESS OF THE PROGRAMME

HAMBURG, GERMANY AND SEATTLE, WA / ACCESSWIRE / April 18, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) and Variant Bio, Inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis.

Fibrosis is characterised by marked and pathogenic build-up of the tissue matrix, leading to tissue degeneration in organs, including the liver and lungs. Fibrotic disease contributes substantially to global mortality and morbidity. Despite the chronic nature of fibrotic conditions, widespread impact on various organs, and substantial disease burden, there is currently no curative treatment for these conditions.

The strategic partnership leverages Variant Bio's cutting-edge genomic discovery capabilities and VB-Inference platform as well as Evotec's extensive expertise in antifibrotic drug discovery. Evotec will identify best-in-class small molecules targeting a key fibrotic pathway with strong genetic support identified by Variant Bio and progress the programme towards the selection of a clinical development candidate(s) using Evotec's integrated end-to-end R&D platform. Additionally, the collaboration includes an opportunity to evaluate unrelated nephrology targets based on human multi-omics data with Evotec's molecular patient database ("E.MPD").

Under the terms of the risk-sharing partnership, Evotec will receive undisclosed research funding and may receive pre-clinical and clinical milestones and/or royalties dependent on the success of the programme. This strategic framework allows Variant Bio to offset the early costs of drug development in exchange for a portion of the future upside.

Dr Matthias Evers, Chief Business Officer of Evotec, said: "We are excited to enter this collaboration with Variant Bio. Variant's genomics-focused model which identifies novel drug targets perfectly aligns with Evotec's data-driven approach to redefine diseases at the molecular level and enhance probability of success. We look forward to combining our complementary drug discovery platforms in a capital efficient partnership and drive new, best-in-class fibrosis treatments together."

So handeln Sie das Kursziel

Der Analyst erwartet ein Kursziel von 10,17€, was eine Steigerung von +4,41% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.

 

Morgan Stanley

 

Alle Partner

Übernehmen

Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
Bitte verändern Sie Kursziel, Zeitraum oder Emittent.Alternativ können Sie auch unsere Derivate-Suchen verwenden
Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche

WerbungDisclaimer